Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||ZEN-3694||Preclinical - Pdx||Actionable||In a preclinical study, ZEN-3694 treatment inhibited tumor progression in an AR-positive cell line xenograft model and an AR V7_splice-positive cell line xenograft model of prostate cancer, and inhibited tumor progression in an Xtandi (enzalutamide)-resistant patient-derived xenograft (PDX) model (Cancer Res 2016;76(14 Suppl):Abstract nr LB-207).||detail...|
|PubMed Id||Reference Title||Details|
|Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC)||Full reference...|